The First Probable Case of Hereditary Angioedema in Vietnam

Khanh Bui Van, Doan Nguyen Van*

The Center of Allergy and Clinical Immunology, Bach Mai Hospital, Hanoi, Vietnam

INTRODUCTION

Hereditary angioedema (HAE) is rare disorder due to C1-inhibitor deficiency (C1-INH) that are debilitating and may be life-threatening. HAE is a lack of consensus concerning diagnosis, therapy, and management, particularly in Vietnam. In this case report, we report a 40-year-old male patient with typical clinical symptoms and family history but he showed normal C4 level, and we could not measure C1q and C1-INH level. However, the diagnosis of HAE can be made based on typical clinical symptoms and the favorable prophylactic response to danazol treatment. Based on these findings, we suggest that he has type I HAE, although he showed normal C4 level.

Key Words: Hereditary angioedema; Vietnam

CASE REPORT

The patient, a 40-year-old man, had a 16-year history of recurrent weekly abdominal pain and swelling of the hands and lips without urticaria, in association with trauma or psychological and physical stress. He visited the emergency room after a day of hard work during which he developed severe swelling of the lips, around the eyes, and of the right hand (the left hand was normal), without urticaria or dyspnea. The symptoms had progressed gradually over time. He had not taken any medications for his symptoms. He denied a history of drug use, including use of anti-hypertensive agents. The patient had a brother who had died of recurrent facial and laryngeal swelling 5 years earlier. The physical examination revealed a normal heart rate with regular rhythm, normal oxygenation, and normal blood pressure. Diffuse swelling of his face, both lips, and right hand were noted (Figs. 1 and 2). He was treated with subcutaneous epinephrine and systemic antihistamine and corticosteroid. One day later, the patient was better and was discharged.

In view of the clinical and family histories and clinical presentation of this patient, we diagnosed HAE, despite a normal complement C4 level. We could not measure the C1 esterase inhibitor (C1-INH) level, as this test is not available in our country. To prevent acute attacks of HAE, we started danazol 200 mg per day for 1 month, according to the Milan protocol for prophylaxis at the outpatient clinic, and observed no episodes of HAE during that month. We reduced the dose of danazol to 100 mg per day. There were no episodes of swelling and no adverse reactions for more than 2 months.

DISCUSSION

Landerman et al. characterized HAE in 1962. The role of C1-INH in regulating the contact system by inactivating both plasmin activators.

Correspondence to: Doan Nguyen Van, MD, PhD, The Center of Allergy and Clinical Immunology, Bach Mai Hospital & Department of Allergy and Clinical Immunology, Hanoi Medical University, 78 Giai Phong Road, Dong Da, Hanoi, Vietnam.
Tel: +84-4-913-351-356; Fax: +84-4-3869-1607; E-mail: mr.doan1956@yahoo.com.vn
Received: September 17, 2011; Revised: November 5, 2011; Accepted: November 10, 2011

• There are no financial or other issues that might lead to conflict of interest.
HAE has a strong family history associated with a quantitative (type I) or qualitative (type II) deficiency of C1-INH caused by mutations of the C1-INH gene. Type I HAE (85% of cases) presents with reduced C1-INH protein and function, while in type II (15% of cases), C1-INH has normal protein levels, but reduced function. Type III HAE, which presents with normal C1-INH protein and function, is an estrogen-dependent inherited form found mostly in females, with an otherwise unknown defect.

The diagnosis of HAE is based on the typical clinical symptoms, family history, and laboratory findings such as lower C4, C1q, and C1-INH levels. Our patient had typical clinical findings with a positive family history, but a normal C4 level. Although this might have been a laboratory error, some cases of HAE with a normal C4 level have been reported. We could not measure the C1q or C1-INH level. In addition, the diagnosis of HAE can be based on a favorable clinical response to danazol treatment according to the Milan protocol for prophylaxis. Based on these findings, we postulate that our patient has type I HAE, even though he had a normal C4 level. He will require danazol therapy and long-term monitoring.

Approaches to the diagnosis and management of HAE vary among countries, as a full laboratory setting and some treatments are not available in developing countries. Earlier treatments were developed empirically and include the fibrinolysis inhibitors epsilon aminocaproic acid and tranexamic acid and attenuated androgens such as danazol. In recent years, new agents such as C1 esterase inhibitor protein replacement products, a plasma kallikrein inhibitor, and a bradykinin receptor antagonist have been introduced.

To prevent acute attacks, we used danazol, which is the only drug available in Vietnam, based on results using danazol in HAE prophylaxis. We prescribed danazol for 3 months and found that 100 mg of danazol daily prevented acute attacks of HAE in our patient.

In conclusion, we report the first probable case of HAE in Vietnam successfully treated with danazol. The diagnosis was based on the typical clinical symptoms, positive family history, and successful treatment with danazol. Further investigations are needed to identify more patients and define their clinical and laboratory findings in Vietnam.

REFERENCES

1. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med 2001;161:2417-29.
2. Khan DA. Hereditary angioedema: Historical aspects, classification, pathophysiology, clinical presentation, and laboratory diagnosis. Allergy Asthma Proc 2011;32:1-10.
3. Bowen T, Brosz J, Brosz K, Hebert J, Ritchie B. Management of hereditary angioedema: 2010 Canadian approach. Allergy Asthma Clin Immunol 2010;6:20.
4. Bowen T, Cicardi M, Farkas H, Bork K, Kreuz W, Zingale L, Varga L, Martínez-Saguer I, Ayyüren-Pürsün E, Binkley K, Zurar B, Davis A 3rd, Hebert J, Ritchie B, Burnham J, Castaldo A, Menendez A, Nagy I, Harmat G, Bucher C, Lacuesta G, Isaacutz A, Warnont R, Yang W, Dean J, Kanani A, Stark D, McCusker C, Wagner E, Rivard GE, Leith E, Tsai E, MacSween M, Lyang A, Serushago B, Lesnoff A, Waserman S, de Serres J. Canadian 2003 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. J Allergy Clin Immunol 2004;114:629-37.
5. Huang YT, Lin YZ, Wu HL, Chiu TF, Lee KM, Tsai HY, Yang SC, Huang FY. Hereditary angioedema: a family study. Asian Pac J Allergy Immunol 2005;23:229-33.
6. Gower RG, Pursun EA, Barakat AJ, Caballero T, Busse PJ, Lorton MD, Farkas H, Hurewitz DS, Jacobs JS, Johnston DT, Lumry W, Maurer M. Hereditary angioedema caused by C1-esterase inhibitor deficiency: a literature-based analysis and clinical commentary on prophylaxis treatment strategies. World Allergy Organ J 2011; 4:S9-21
7. Wen DC, Shyr SD, Wu JY, Lin CC, Chiang YC, Huang LH, Lin MT, Yang HC, Liang PH. Hereditary angioedema: a Taiwanese family with a novel gene mutation. Asian Pac J Allergy Immunol 2007;25:163-7.
8. Bowen T. Hereditary angioedema: beyond international consensus - circa December 2010 - The Canadian Society of Allergy and Clinical Immunology Dr. David McCourtie Lecture. Allergy Asth-
9. Zuraw BL. Novel therapies for hereditary angioedema. Immunol Allergy Clin North Am 2006;26:691-708.
10. Bork K. Diagnosis and treatment of hereditary angioedema with normal Cl inhibitor. Allergy Asthma Clin Immunol 2010;6:15.
11. Landerman NS, Webster ME, Becker EL, Ratcliffe HE. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy 1962;33:330-41.
12. Davis AE 3rd. Mechanism of angioedema in first complement component inhibitor deficiency. Immunol Allergy Clin North Am 2006;26:633-51.
13. Binkley KE. Factor XII mutations, estrogen-dependent inherited angioedema, and related conditions. Allergy Asthma Clin Immunol 2011;7:1.
14. Tarzi MD, Hickey A, Förster T, Mohammadi M, Longhurst HJ. An evaluation of tests used for the diagnosis and monitoring of Cl inhibitor deficiency: normal serum C4 does not exclude hereditary angio-oedema. Clin Exp Immunol 2007;149:513-6.
15. Riedl MA. Update on the acute treatment of hereditary angioedema. Allergy Asthma Proc 2011;32:11-6.
16. Zuraw BL. HAE therapies: past present and future. Allergy Asthma Clin Immunol 2010;6:23.
17. Frank MM. Update on preventive therapy (prophylaxis) of hereditary angioedema. Allergy Asthma Proc 2011;32:17-21.